Rini, B. I., George, D. J., Michaelson, M. D., Rosenberg, J. E., Bukowski, R. M., Sosman, J. A., … Baum, C. M. (2006). Phase II study of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (MRCC). In ANNALS OF ONCOLOGY (Vol. 17, pp. 144–144). Istanbul, TURKEY: OXFORD UNIV PRESS.

Rini, Brian I., Daniel J. George, M Dror Michaelson, Jonathan E. Rosenberg, Ronald M. Bukowski, Jeffrey A. Sosman, Walter M. Stadler, Kim Margolin, Thomas E. Hutson, and Charles M. Baum. “Phase II study of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (MRCC).” In ANNALS OF ONCOLOGY, 17:144–144. OXFORD UNIV PRESS, 2006.

Rini BI, George DJ, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, et al. Phase II study of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (MRCC). In: ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2006. p. 144–144.

Rini, Brian I., et al. “Phase II study of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (MRCC).” ANNALS OF ONCOLOGY, vol. 17, OXFORD UNIV PRESS, 2006, pp. 144–144.

Rini BI, George DJ, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Margolin K, Hutson TE, Baum CM. Phase II study of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (MRCC). ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2006. p. 144–144.